Loading...
•
Mar 31, 2020
CareDx Q1 2020 Earnings Report
Reported strong first quarter results with revenue growth driven by testing services and recent acquisitions.
Key Takeaways
CareDx reported a strong first quarter with a 48% year-over-year increase in total revenue, reaching $38.4 million. The company saw growth in testing services, product revenue, and digital solutions. While the net loss was $5.8 million, non-GAAP net income was $0.2 million. Due to COVID-19 uncertainties, CareDx withdrew its 2020 guidance on April 8, 2020.
Total revenue reached $38.4 million, a 48% increase year-over-year.
Over 15,000 AlloSure Kidney and AlloMap Heart patient results were provided.
The company recorded its seventh straight quarter of positive adjusted EBITDA.
Cash reserves were strengthened to approximately $80 million.
RemoTraC, a service for at-home blood draws, was successfully introduced.
Revenue by Segment
Forward Guidance
Due to the continued uncertainties from the impact of COVID-19, CareDx withdrew its 2020 guidance on April 8, 2020.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...